Acasti Pharma Inc ACST

Healthcare

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.

NDAQ:ACST - Post by User

Acasti Pharma Inc > Open for Answers

<< Previous

Bullboard Posts

Next >>

Comment by Francine01on Jun 23, 2020 12:20pm

175 Views

Post# 31181311

RE:RE:RE:RE:Open for Answers

I don't agree. the only relevant important information that will be disclose is what was the active ingredient in the placebo / 5 sites arm. The rest is irrelevant. because the only thing which important is that Capre work or not and I do believe it work with no AE. You won't have any answer for T2. Even after T2 is unblind. the most important fact is the HbA1C marker for diabetics. If we hit this marker, it will be the holy grail.

I do believe that that the reason that the T1 placebo reacted will be a rationnal explanation (ie, statins). I am sure that the information is already leaked and thats why the is no significant sell off.

GLTA

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions